Deferoxamine
- Generic Name
- Deferoxamine
- Brand Names
- Desferal
- Drug Type
- Small Molecule
- Chemical Formula
- C25H48N6O8
- CAS Number
- 70-51-9
- Unique Ingredient Identifier
- J06Y7MXW4D
- Background
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
- Indication
Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
- Associated Conditions
- Aluminum overload, Chronic Iron Overload, Chronic aluminum overload, Iron Overload
- Associated Therapies
- -
Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Aswan University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT05748587
- Locations
- 🇪🇬
Aswan University Hospital, Aswan, Egypt
Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
- Conditions
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT04633889
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Aditya S. Pandey, MD
- Target Recruit Count
- 120
- Registration Number
- NCT04566991
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇨🇳Peking University Health Science Center, Beijing, Beining, China
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Abderrahmane Mami Hospital
- Target Recruit Count
- 260
- Registration Number
- NCT04361032
- Locations
- 🇹🇳
Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia
Application of Desferal to Treat COVID-19
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT04333550
- Locations
- 🇮🇷
Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 350
- Registration Number
- NCT04292314
- Locations
- 🇸🇦
Maternity and Children hospital, Mecca, Saudi Arabia
🇪🇬Health insurance hospital, Banī Suwayf, Egypt
🇪🇬Faculty of medicine, Beni-suef univeristy - Beni-Suef university hospital, Banī Suwayf, Egypt
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 174
- Registration Number
- NCT03137966
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03085771
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02875262
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 180
- Registration Number
- NCT02367248
- Locations
- 🇨🇳
Department of Neurology，Beijing Shijitan Hospital，Capital Medical University, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.